b**u
发帖数: 2761 | 1 By PETER LOFTUS
Merck & Co. said Friday that it would widen its cost-cutting measures by
eliminating up to 13,000 jobs—on top of the 17,000 layoffs in prior actions
—as the drug maker faces generic competition and other pressures.
The Whitehouse Station, N.J., company disclosed the job cuts as it reported
a near-tripling of second-quarter earnings on a tax benefit and other items.
Revenue rose 7% on sales growth for diabetes drugs Januvia and Janumet, as
well as anti-inflammatory drug Remicade.
The new round of layoffs, due to be completed by 2015, means that Merck will
have eliminated about 30% of the work force it had at the end of 2009, in
the wake of its acquisition of Schering-Plough. Some of the reductions have
been offset by new hiring, however.
Merck said the new layoffs would save the company an additional $1.3 billion
to $1.5 billion in annual costs, on top of the expected $3.5 billion in
annual savings it expects to achieve by the end of 2012 from previously
announced cost-cutting actions. Merck's work force as of June 30 was 91,000.
"The realities of our environment dictate the need to operate more flexibly
and nimbly from a lower cost base," Merck Chief Executive Kenneth Frazier
said on a conference call with analysts. He said the company would reinvest
some of the savings in new growth opportunities when appropriate.
The cuts will come in administrative and headquarters jobs, consolidation of
office facilities, and the ongoing sale or closure of manufacturing plants,
including in the company's animal-health unit.
Merck spokesman David Caouette said 35% to 40% of the new work-force
reductions will be in the U.S., while Merck will continue to hire new
employees in "growth areas," including emerging markets such as China.
For the year, the company raised the lower end of its per-share earnings
forecast by two cents and now expects $3.68 to $3.76, while affirming its
revenue guidance. It also reduced the top end of its 2011 research and
development spending target by another $100 million and now expects $8
billion to $8.3 billion in R&D spending.
Merck also said it is discontinuing development of an experimental migraine
drug, telcagepant, after assessing the clinical data. Analysts once
predicted this drug could generate more than $1 billion in annual sales, but
those expectations began to diminish when Merck delayed its filing plans in
2009.
Like other drug makers, Merck has been forming collaborations and adding
licensing and marketing agreements to help blunt the effects of coming
patent expirations for top drugs. Merck faces the loss next year of patent
protection for asthma drug Singulair, its best-selling drug, which will
expose it to sales-eroding generic competition.
Merck already has seen generic competition for previous big sellers temper
its sales growth. As it strives to bolster its drug pipeline, Merck has
reduced its research-and-development spending plans less than the steep cuts
by rival Pfizer Inc.
For the second quarter, Merck reported a profit of $2.02 billion, or 65
cents a share, up from $752 million, or 24 cents a share, a year earlier.
Excluding the tax benefit and other items, per-share earnings rose to 95
cents from 86 cents. Revenue increased to $12.15 billion.
Analysts polled by Thomson Reuters had forecast earnings of 95 cents a share
on revenue of $11.78 billion.
Gross margin rose to 64.7% from 59.9%.
Pharmaceutical sales grew 7.4% to $10.36 billion. Remicade sales climbed 26%
, Singulair sales jumped 7.6% and Januvia increased 30%.
Merck recently won regulatory approval for a new hepatitis C drug, Victrelis
, and said the U.S. launch is under way.
The animal-health business, which includes products for farm animals and
pets, saw 10% revenue growth. Merck's consumer division, which includes over
-the-counter allergy medicine Claritin and Coppertone skin-care products,
posted a sales decline of 1%.
Merck shares closed Thursday at $34.93 and were inactive premarket. The
stock is down 3.1% this year.
http://online.wsj.com/article/SB1000142405311190480030457647575 | s*****l
发帖数: 1844 | 2 not surprised. get used to it. And, this is not the end... | a*******s
发帖数: 1539 | 3 加起来3w呀，转行算了，亏我还给merck投了那么多简历
actions
reported
items.
as
will
【在 b**u 的大作中提到】
: By PETER LOFTUS
: Merck & Co. said Friday that it would widen its cost-cutting measures by
: eliminating up to 13,000 jobs—on top of the 17,000 layoffs in prior actions
: —as the drug maker faces generic competition and other pressures.
: The Whitehouse Station, N.J., company disclosed the job cuts as it reported
: a near-tripling of second-quarter earnings on a tax benefit and other items.
: Revenue rose 7% on sales growth for diabetes drugs Januvia and Janumet, as
: well as anti-inflammatory drug Remicade.
: The new round of layoffs, due to be completed by 2015, means that Merck will
: have eliminated about 30% of the work force it had at the end of 2009, in
| L*******a
发帖数: 824 | 4 都是pipeline出了问题 老药一个一个的死了 新药一个也出不来 r&d还是需要加大
投入啊 | l**k
发帖数: 360 | 5 留点钱也不准备投RD了
都准备着看哪个小公司的东西不错直接买了来补充pipeline
【在 L*******a 的大作中提到】
: 都是pipeline出了问题 老药一个一个的死了 新药一个也出不来 r&d还是需要加大
: 投入啊
| he
发帖数: 2025 | 6 Patent Expiring in 2011 (2010美国销售额)
Lipitor---Pfizer---$5,329,000,000
Zyprexa---Eli Lily---$2,496,000,000
Diovan---Novartis---$1,443,539,000
Levaquin---J & J---$1,312,000,000
Concerta---J & J---$929,000,000
Protonix---Pfizer---$690,000,000
.
.
Patent Expiring in 2012
Plavix---Bristol-Myers Squibb---?
Sanofi---Aventis---$6,154,000,000
Seroquel---AstraZeneca---$3,747,000,000
Singulair---Merck---$3,224,000,000
Actos---Takeda---$3,351,000,000
Enbrel---Amgen---$3,304,000,000
传言:
除了默克，Novartis准备20%-30%裁员，辉瑞也少不了，Lipitor一个药
就是一百二十亿的产品，占辉瑞总营收30%了。 | s*****l
发帖数: 1844 | 7 Do not forget Lilly. Lilly's situation is worst among big pharmas, as far as
patent expiration by 2015 (or 2020) is considered.
Where did you get the info that Novartis is cutting 20-30% people??
【在 he 的大作中提到】
: Patent Expiring in 2011 (2010美国销售额)
: Lipitor---Pfizer---$5,329,000,000
: Zyprexa---Eli Lily---$2,496,000,000
: Diovan---Novartis---$1,443,539,000
: Levaquin---J & J---$1,312,000,000
: Concerta---J & J---$929,000,000
: Protonix---Pfizer---$690,000,000
: .
: .
: Patent Expiring in 2012
| he
发帖数: 2025 | 8 一个幸存下来的销售，两年前他就开始准备最坏的情况。
以前这帮人风光无限，俊男靓女，轻轻松松十几二十万一年。
as
【在 s*****l 的大作中提到】
: Do not forget Lilly. Lilly's situation is worst among big pharmas, as far as
: patent expiration by 2015 (or 2020) is considered.
: Where did you get the info that Novartis is cutting 20-30% people??
| s*****l
发帖数: 1844 | 9 20-30% is a lot of people... From what I know, Novartis does not seem to be
so bad....
【在 he 的大作中提到】
: 一个幸存下来的销售，两年前他就开始准备最坏的情况。
: 以前这帮人风光无限，俊男靓女，轻轻松松十几二十万一年。
:
: as
| he
发帖数: 2025 | 10 还是传言而已，辉瑞恐怕短期内受的冲击更大，Lipitor今年就要过期鸟。
be
【在 s*****l 的大作中提到】
: 20-30% is a lot of people... From what I know, Novartis does not seem to be
: so bad....
| t**n
发帖数: 4365 | 11 明年应该就轮到novartis了
be
【在 s*****l 的大作中提到】
: 20-30% is a lot of people... From what I know, Novartis does not seem to be
: so bad....
| s*****l
发帖数: 1844 | 12 Pfizer has long prepared for the Lipitor expiration. They are layoffing
people in the past 5 years already. Seems still far away from stablizing.
【在 he 的大作中提到】
: 还是传言而已，辉瑞恐怕短期内受的冲击更大，Lipitor今年就要过期鸟。
:
: be
| b******e
发帖数: 3348 | 13 为什么等到偶们工作的时候都是这样的悲催情况呢。
【在 he 的大作中提到】
: 一个幸存下来的销售，两年前他就开始准备最坏的情况。
: 以前这帮人风光无限，俊男靓女，轻轻松松十几二十万一年。
:
: as
| O*******f
发帖数: 926 | 14 裁人有华尔街的因素在里面，就是所谓的“shareholder”。为了做出好看的财务报表
，只好裁人了。Merck的这次裁人的数目，多少有些意外，看来是酝酿了比较长的时间
了，感觉像要一刀了断似的，彻底瘦身，从而保证未来2-3年的sharehold的利益。 |
|
